Vardenafil hydrochloride
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Erectile |
| Polymorphic form | Trihydrate form |
| CAS No. | 330808-88-3 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Vardenafil is an oral therapy for erectile dysfunction that selectively inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, which activates guanylate cyclase and increases cGMP synthesis in the smooth muscle cells. PDE5 inhibitors like vardenafil prevent the degradation of cGMP, enhancing blood flow into the penis and resulting in an erection. Vardenafil is more potent than sildenafil and tadalafil in inhibiting PDE5, but it has lower selectivity for other PDE isoforms compared to tadalafil.
Polpharma API
- Long experience in commercial manufacturing
- Extensive portfolio of PDE-5 inhibitors (Sildenafil, Tadalafil)
- Wide regulatory documentation
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
